Compare SRL & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRL | ALDX |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.5M | 101.1M |
| IPO Year | 1996 | 2014 |
| Metric | SRL | ALDX |
|---|---|---|
| Price | $6.13 | $1.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 12.8K | ★ 891.7K |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | ★ 16.07% | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.13 | $1.07 |
| 52 Week High | $10.39 | $6.18 |
| Indicator | SRL | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 28.74 | 36.50 |
| Support Level | $5.37 | $1.48 |
| Resistance Level | $6.44 | $1.88 |
| Average True Range (ATR) | 0.35 | 0.09 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 48.57 | 12.68 |
Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.